Trikafta (elexacaftor / tezacaftor / ivacaftor)

The most widely prescribed CF treatment, eligible for about 90% of patients. Two morning tablets plus one evening tablet restore function to the defective CFTR protein that causes cystic fibrosis.

Trikafta is a three-part medicine that works like a team to fix the broken CFTR protein in cystic fibrosis. Two parts (elexacaftor and tezacaftor) are 'correctors' that help the broken protein fold correctly so it can reach the cell surface. The third part (ivacaftor) is a 'potentiator' that helps the protein stay open and let salt and water flow through, making mucus thinner and easier to cough up.

Trikafta has a boxed warning: it can cause serious liver injury and liver failure, including cases leading to liver transplant and death. Liver blood tests are needed before starting, every month for the first 6 months, every 3 months for the next 12 months, then at least once a year. Trikafta should not be used by people with severe liver impairment and is not recommended for people with moderate liver impairment. Other warnings include allergic reactions, raised pressure in the skull (unusual headache or vision changes), mood changes including depression and suicidal thoughts, and cataracts in children. Common side effects include headache, upper respiratory infection, stomach pain, diarrhea, rash, and raised liver enzymes. Avoid grapefruit. Do not take Trikafta with strong CYP3A inducers such as rifampin or St. John's wort, and tell your doctor about all your medicines because some require a lower Trikafta dose. Tell your doctor right away if you have dark urine, yellow skin or eyes, or pain on the right side of your belly.

Trikafta tablets are taken twice daily with a meal containing fat (like eggs, pizza, or ice cream) because fat helps your body absorb the medicine. For children ages 2 to 5, Trikafta comes as oral granules mixed with a teaspoon of soft food or liquid. Most insurance plans cover it for patients with at least one F508del mutation.

Yes, Elexacaftor / Tezacaftor / Ivacaftor (Trikafta) is FDA approved (2019) for the treatment of Cystic Fibrosis.

Before Trikafta, CFTR modulators only worked for small subsets of CF patients with specific mutations. Trikafta expanded eligibility to approximately 90% of people with CF by working on the most common mutation, F508del, plus hundreds of others. Clinical trials showed dramatic improvements in lung function, reduced pulmonary exacerbations, and improved quality of life. For many patients, it has transformed CF from a progressively debilitating disease into a more manageable chronic condition.

The active ingredients in Trikafta are absorbed much more effectively when taken with food containing fat. Without fat, your body absorbs significantly less of the drug, which can reduce its effectiveness. A meal or snack with at least a moderate amount of fat (examples include eggs, avocado, peanut butter, cheese, or whole milk) is recommended. This applies to both the morning and evening doses.

Trikafta is approved for patients age 2 and older with at least one CFTR variant that either responds to Trikafta based on clinical or lab data or leads to production of CFTR protein (this includes F508del). Your CF care team can check your specific genotype against the FDA-approved mutation list, which is available on Vertex's eligibility tool at trikafta.com. If you have not had CFTR genetic testing, your doctor can order it. Most CF centers now test for mutations as part of routine diagnosis.

If 6 hours or less have passed since a missed morning or evening dose, take it as soon as possible with fat-containing food and keep your usual schedule. If more than 6 hours have passed since a missed morning dose, take the missed morning dose as soon as possible with fat-containing food and skip that evening dose. If more than 6 hours have passed since a missed evening dose, skip it and take your next morning dose at the usual time. Never take the morning and evening doses at the same time. Do not double up doses. Consistency matters because maintaining steady drug levels helps keep the CFTR protein functioning properly. If you frequently miss doses, talk to your care team about strategies to stay on track.

Trikafta can significantly improve lung function (measured by FEV1) and reduce the frequency of pulmonary exacerbations, but it does not reverse structural lung damage like bronchiectasis or scarring that has already occurred. Patients who start Trikafta earlier in their disease course, before significant structural damage develops, tend to see the greatest long-term benefit. Even patients with advanced lung disease can experience meaningful improvements in mucus clearance and infection frequency.

Both are triple-combination CFTR modulators from Vertex Pharmaceuticals that cover a similar range of mutations. The main practical difference is dosing: Trikafta requires 2 doses per day (morning and evening), while Alyftrek (approved December 2024) is taken once daily. In clinical trials, Alyftrek showed non-inferior efficacy and was superior to Trikafta in reducing sweat chloride, a biomarker of CFTR function. Your CF care team can help you decide whether the once-daily convenience of Alyftrek is worth discussing a switch.

Yes. Trikafta addresses the underlying protein defect but does not eliminate the need for standard CF care. Airway clearance techniques, inhaled medications (like hypertonic saline and dornase alfa), pancreatic enzyme supplementation, and regular CF clinic visits remain important parts of your treatment plan. Your care team may adjust specific therapies based on how you respond to Trikafta, but stopping supportive treatments without medical guidance is not recommended.